Core Viewpoint - The announcement details a significant change in the voting rights held by The Goldman Sachs Group, Inc. in Kontron AG, indicating an increase in their stake and potential influence over the company [3][4]. Group 1: Notification Details - The notification was made after the deadline, highlighting the importance of compliance with major holdings notification rules under BörseG 2018 [2]. - The threshold for voting rights was crossed on January 7, 2026, with Goldman Sachs now holding a total of 4.04% of voting rights in Kontron AG [3]. Group 2: Voting Rights Breakdown - The breakdown of voting rights shows that Goldman Sachs holds 0.49% directly through shares and 3.55% through financial instruments [3][5]. - The total number of voting rights held by Goldman Sachs is 63,568, an increase from the previous notification where they held 3.89% [3][4]. Group 3: Financial Instruments - Goldman Sachs has various financial instruments contributing to their voting rights, including 704 voting rights from securities lending, representing 2.67% [6]. - Additional financial instruments include swaps and call warrants, which contribute an additional 0.88% to their voting rights [7]. Group 4: Shareholder Structure - The Goldman Sachs Group, Inc. is not controlled by any other entity and does not control any other undertakings holding interests in Kontron AG [8]. - The detailed chain of controlled undertakings shows various subsidiaries of Goldman Sachs, with the largest direct holdings being 2.33% through Goldman Sachs International [8][9].

Key Points The investment thesis for AI is still intact and growing, despite the recent short-term correction in the sector. AI is already delivering tangible financial results while allowing companies to improve their products and services. Chipmakers will continue to win, but looking at all the other bottlenecks limiting the pace of the AI buildout reveals a host of other companies that could be big winners from the trend. 10 stocks we like better than Nvidia › Many AI stocks struggled in Dece ...

Core Viewpoint - BNY, the world's largest custodian bank, is set to issue digital representations of customer deposits on the blockchain, marking a significant step in enhancing its digital cash capabilities [1] Group 1: Digital Asset Initiatives - BNY's tokenized deposits will serve as digital book entries that clients can withdraw through traditional means, initially focusing on collateral and margin applications [2] - The introduction of tokenized deposits aims to reduce settlement friction and improve liquidity efficiency, showcasing how traditional financial institutions are integrating digital assets into their operations [3] Group 2: Institutional Trust and Scale - BNY has safeguarded $57.8 trillion in assets for clients as of September and manages $2.1 trillion in assets, emphasizing the trusted nature of its banking services [4] - The bank's digital infrastructure will include a tokenized money-market fund in collaboration with Goldman Sachs, further solidifying its position in the digital finance landscape [4] Group 3: Industry Response and Collaboration - The formation of BNY's digital assets unit in 2021 led to the management of private keys and the launch of custody services for Bitcoin and Ethereum [5] - Statements from various crypto-native firms, including Anchorage Digital and Circle, highlight the significance of BNY's move towards tokenized deposits as a milestone for digital cash adoption [6]

Core Viewpoint - Broadcom Inc. (NASDAQ:AVGO) has seen a significant share price increase of 49% over the past year, driven by its strong position in the AI chip market and positive analyst sentiment [2]. Company Performance - Broadcom's shares have gained 49% over the past year, benefiting from AI-generated attention due to its custom chip design capabilities [2]. - Goldman Sachs added Broadcom to its US Conviction List with a price target of $450 and a Buy rating on January 5th, citing the company's strong position in the enterprise silicon market [2]. - UBS raised Broadcom's price target to $475 from $472 while maintaining a Buy rating in December [2]. Executive Leadership - Jim Cramer praised Broadcom's CEO, Hock Tan, as one of the best executives in the technology industry, indicating strong leadership at the company [2]. Market Trends - Cramer highlighted a shift where hardware stocks, like Broadcom, are outperforming software stocks, suggesting a changing landscape in the tech industry [3].

Core Insights - Earnings season is approaching, with Goldman Sachs analysts suggesting that traders expect the average S&P 500 stock to move 4.5% post-earnings, indicating low implied volatility compared to historical levels [2][3] - Despite the low expectations, Goldman believes that fundamental drivers of earnings volatility remain intact [3] Sector Analysis - Goldman identifies utilities, healthcare, materials, and industrials as sectors with the most potential for post-earnings volatility, with utilities showing abnormal volatility in recent quarters [5] - In contrast, volatility has decreased in most other sectors, including technology, over the past year [5] Earnings Estimates and Stock Performance - Goldman has raised its S&P 500 earnings estimates by 5% and its price target for the index by 8% over the past three months, while the index itself only rose 3%, suggesting that improvements in fundamentals are outpacing stock price increases [6] - Individual investors have been aggressive buyers of single stocks and ETFs, which is viewed positively for future equity performance [6] Investment Opportunities - Goldman has identified 25 stocks with "out-of-consensus" earnings views, indicating potential for traders to profit from options strategies [6] - Notable companies expected to surprise positively include Meta Platforms, UnitedHealth Group, Arista Networks, and Robinhood, where buying out-of-the-money call options could be beneficial [8] - Conversely, Texas Instruments and Southwest Airlines are expected to face margin pressure, suggesting that buying slightly out-of-the-money put options could be profitable if their earnings disappoint [9]

Group 1 - CNBC commentator Jim Cramer advises investors to avoid hastily buying stocks that have already seen significant increases, suggesting a wait for better entry points instead of chasing stocks that have risen by 30% or 40% this year [2] - Cramer highlights potential near-term risks in the banking sector ahead of the upcoming earnings season, noting that while banks are undervalued, stocks like JPMorgan Chase may be temporarily affected by cautious comments from CEO Jamie Dimon [2][4] - Goldman Sachs warns that high valuations could lead to increased market volatility if corporate performance does not meet expectations, making Cramer's advice to wait for better entry points particularly relevant [5] Group 2 - Over the past year, Invesco QQQ Trust, Series 1 (NASDAQ:QQQ) and Vanguard S&P 500 ETF (NYSE:VOO) have climbed 22.33% and 18.76%, respectively, indicating strong market performance [5]

Core Insights - JPMorgan Chase will replace Goldman Sachs as the issuer of the Apple Card, with the transition expected to take place in about two years [2][8] - Consumers' existing Apple credit-card and savings balances, payment history, credit limit, and Daily Cash balance will carry over during the transition [3][8] Group 1: Transition Details - The transition will affect who holds the money and services the accounts for Apple Card and Apple Savings users, but balances and rewards are expected to move automatically [4] - Current Apple Card customers will have the option to open an Apple Savings account with JPMorgan or retain their existing account with Goldman Sachs [5][8] Group 2: Account Features - The current Apple Savings account has no monthly fees or minimum balance requirements and is federally insured for balances up to $250,000, offering a 3.65% APY [6] - Chase does not currently offer a high-yield savings account but plans to develop its own savings product in association with the Apple Card [6] Group 3: Payment Network and Terms - Mastercard will continue as the payment network for the Apple Card, and no changes to the terms of the Apple Card are expected [7] - Credit reports will be updated to reflect Chase as the issuing bank, with further details to be communicated to users as the transition date approaches [7]

Core Viewpoint - Bank of America analysts upgraded Coinbase to "Buy" from "Neutral," citing its leadership in tokenization and potential benefits from its blockchain network [1] Group 1: Product Developments - Coinbase recently launched Coinbase Tokenize, which offers asset managers services like issuance, custody, compliance, and access to a large client base [3] - The exchange's product offerings are expanding, including stock trading and prediction markets, which could enhance revenue streams [1][3] - Coinbase's Ethereum layer-2 scaling network, Base, is being utilized to expand its blockchain infrastructure, supporting products like Bitcoin-backed lending [4] Group 2: Market Position and Growth Potential - Analysts believe Coinbase is uniquely positioned in the market as asset managers show interest in digital representations of securities, highlighting a non-consumer-facing product [2] - The growth areas for Coinbase's tokenization vision include stocks, ETFs, real estate, and private companies [3] - The potential launch of a native currency for Base could provide significant financial benefits to Coinbase, with analysts estimating it could raise billions of dollars [5][6] Group 3: Stock Performance - Coinbase shares were trading around $248, reflecting a 1% increase, but are approximately 40% below their July high of $444 [4] - Analysts noted an increase in the exchange's "product velocity," indicating a positive outlook for future performance [4]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Goldman Sachs despite higher revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - Goldman Sachs is expected to report quarterly earnings of $11.69 per share, reflecting a year-over-year decrease of 2.2%, while revenues are projected to be $14.53 billion, an increase of 4.7% from the previous year [3]. - The consensus EPS estimate has been revised 3.99% higher in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative Earnings ESP reading can indicate the likely deviation of actual earnings from consensus estimates, with a positive reading being a strong predictor of an earnings beat [9][10]. - For Goldman Sachs, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.14%, which complicates predictions of an earnings beat [12]. Historical Performance - Goldman Sachs has beaten consensus EPS estimates in the last four quarters, with a notable surprise of +10.26% in the most recent quarter [13][14]. Comparative Analysis - In contrast, Wells Fargo is expected to report earnings of $1.65 per share, a year-over-year increase of 16.2%, with revenues projected at $21.6 billion, up 6% [18][19]. - Wells Fargo's consensus EPS estimate has been revised 1.1% higher, resulting in a positive Earnings ESP of +0.74%, indicating a higher likelihood of beating the consensus estimate [19][20].

Core Insights - Beacon Therapeutics has successfully raised over $75 million in an oversubscribed Series C financing round, led by Life Sciences at Goldman Sachs Alternatives, with participation from the Retinal Degeneration Fund and existing investors [1][2][8] - The funds will be utilized to advance the development of laru-zova, a potential gene therapy for X-linked retinitis pigmentosa (XLRP), and to support the commercialization plans for this product [4][8] - The company is preparing for pivotal data on laru-zova expected in the second half of 2026, which is anticipated to be a significant milestone for the company [2][3] Company Overview - Beacon Therapeutics is a clinical-stage biotechnology company focused on saving and restoring vision for individuals with rare and prevalent ocular diseases, utilizing gene therapy to address severe ocular conditions [6] - The company's pipeline includes treatments for XLRP, geographic atrophy, and other inherited retinal diseases [4][6] Investor Insights - The Series C financing round included participation from notable investors such as Advent Life Sciences, Forbion, Oxford Science Enterprises, and Syncona Limited, indicating strong confidence in Beacon's mission [1][7] - Life Sciences at Goldman Sachs Alternatives, a new investor, aims to support the development of laru-zova and other pipeline candidates, highlighting the strategic partnership between the two entities [3][11] Market Context - XLRP affects over 100,000 patients in the US, with 14% estimated to have this specific condition, underscoring the potential impact of successful treatments in this area [3]